| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q4 2021 Pre-Market | EPS: REV: | ||||
| Q3 2021 Pre-Market | EPS: REV: | -0.15 172.127M | |||
| Q2 2021 Pre-Market | EPS: REV: | ||||
| Q1 2021 Pre-Market | EPS: REV: | 0.14 1.107B | |||
| Q4 2020 Pre-Market | EPS: REV: | -0.03 1.011B | -0.25 891.33M | -0.02 1.253B | 92% 40.58% |
| Q3 2020 Pre-Market | EPS: REV: | -0.06 951.576M | -0.24 844.65M | -0.15 172.127M | 37.5% -79.62% |
| Q2 2020 Pre-Market | EPS: REV: | 0.09 1.31B | -0.16 784.18M | -0.18 527.074M | -12.5% -32.79% |
| Q1 2020 Pre-Market | EPS: REV: | 0.83 1.143B | -0.02 907.75M | 0.14 1.107B | 800% 21.95% |
| Q4 2019 Pre-Market | EPS: REV: | 0.79 1.245B | -0.21 938.64M | -0.03 1.011B | 85.71% 7.71% |
| Q3 2019 Pre-Market | EPS: REV: | 0.35 1.159B | -0.18 874.87M | -0.06 951.576M | 66.67% 8.77% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- DraftKings Analysts Cheer Strong Q4, Sports Betting Growth And SBTech Integration
- Nio Reports Wider Q4 Loss Despite Revenues Topping $1B
- Travere Therapeutics: Q4 Earnings Insights
- Arcturus Therapeutics: Q4 Earnings Insights
- Hanger: Q4 Earnings Insights
- Recap: Xenon Pharmaceuticals Q4 Earnings
- Helios Technologies: Q4 Earnings Insights
- NIO: Q4 Earnings Insights
- Recap: Viela Bio Q4 Earnings
- Recap: FS KKR Capital Q4 Earnings
